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Units (PU) in Spain, and to determine possible differences
according to aetiology. METHODS: Consecutive NeP patients
were recruited in this cross-sectional & retrospective study
between April and December 2004 in PUs. Demographic data,
NeP type and cause, origin of the derivation, and health
resources consumption (drugs, non-pharmacological therapies,
medical visits, hospitalizations, diagnostics tests) were collected
from existing medical records and patient interview. Costs of
resources at their 2004 values were applied to calculate total cost
from the National Health System perspective. Descriptive statis-
tics and ANCOVA models were used. RESULTS: Five-hundred-
four NeP patients of broad aetiology (44% radiculophaty, 21%
neuralgias, 11% neurophaties, 7% entrapment syndromes, 5%
CRPS, 4% central pain), 57.8 + 0.7 years (Mean + SE), 57.6%
women, and 29.6 + 2.2 months of evolution, were enrolled in
the study. Unadjusted monthly average cost was 422 + €36.
Adjusted monthly cost was signiﬁcantly higher than average for
neurophaties (580 + €90, p = 0.011), because of the higher
number of hospitalization days (0.6 + 0.1, p = 0.021) and phar-
macologic costs (162 + €17, p = 0.001). Radiculophaties showed
lower adjusted costs than the average; €287 + €46, p = 0.026,
because of the lower cost of hospitalization; €79 + €38, p =
0.027. CONCLUSIONS: NeP causes a considerable utilization
of health resources with a substantial cost for the National
Health Service. Neurophaties showed the higher cost per month
per patient, whereas that of the radiculophaties was signiﬁcantly
lower than the average.
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OBJECTIVES: To assess the cost per QALY of pregabalin in the
management of peripheral neuropathic pain. METHODS: We
compared pregabalin on top of “usual care” with “usual care”
alone. In this study usual care was deﬁned as a mix of drug ther-
apies, excluding anti-epileptics, because the latter represented
only 9% of current use, and clinical evidence of pregabalin 
was demonstrated versus usual care without anti-epileptics. A
Markov model was developed to simulate the evolution of a
patient cohort over 1-year, and applied cycles of four weeks.
During each cycle, patients remained in one out of four possible
states: severe, moderate or mild pain, and therapy withdrawal.
Both health care-payers and societal perspectives were consid-
ered. Clinical data were obtained from a trial comparing usual
care plus placebo to usual care plus pregabalin, at either 150,
300, or 300/600mg/day (the latter depending on clinical
response). Resulting effects on pain were transformed into tran-
sition-probabilities between different pain levels. Cost and SF36
utility data of pain levels were obtained from a 1-month obser-
vational study in 88 patients. RESULTS: Usual care resulted in
a yearly cost of €6200 compared to €6089 for an all dose pre-
gabalin-mix, meaning a cost saving of 111€ per patient. Utility
increase was 0.01 for the pregabalin-mix (QALY 0.510 usual
care; 0.520 pregabalin-mix). From a societal perspective, usual
care resulted in a cost of €14,350 versus €13,984 with prega-
balin mix, representing a cost saving of €367. MonteCarlo analy-
sis showed cost savings were not signiﬁcant. However, the utility
gain, albeit small, was statistically signiﬁcant. CONCLUSIONS:
A net cost saving with pregabalin was explained by a longer stay
of patients in less-costly mild/moderate states, but was not sig-
niﬁcant, hence pregabalin is cost-neutral when compared to
current care. On the other hand, utilities showed a signiﬁcant
difference, perhaps explained by their small variance.
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OBJECTIVES: To estimate the clinical and economic conse-
quences of parecoxib sodium versus a parenteral opioid post-
surgical pain management strategy in hospital inpatients
undergoing selected major surgeries. METHODS: We developed
a UK model of postsurgical pain management to assess compar-
ative clinical and economic outcomes in persons receiving 
parecoxib or opioids as a parenteral analgesic regimen. Model
parameters were derived from international clinical trial data, a
large US hospital billing database, and published literature. The
model tracks patient cohorts deﬁned by age and gender over the
3-day period following major abdominal, orthopedic, or gyne-
cologic surgery. The parecoxib regimen included adjunctive use
of opioids. The model estimates occurrences of opioid-related
symptoms (“clinically meaningful events” or CMEs), time spent
in a postanesthesia care unit (PACU) or special care unit (SCU),
various pain intensity metrics, and direct medical costs. Model
outcomes include differences by treatment regimen (parecoxib
versus comparator) in CMEs, PACU/SCU time, pain intensity
scores, direct medical costs, and incremental cost-effectiveness
ratios. RESULTS: Base-case estimated hospitalization costs in the
3 days following surgery were £27 per patient lower among pare-
coxib- versus opioid-treated patients. Patients receiving pare-
coxib spent 11 minutes less time, on average, in PACUs and
SCUs than opioid-treated patients. Total CMEs were approxi-
mately 26% lower among parecoxib- versus opioid-treated
patients. Pain intensity scores were uniformly lower (by a range
of 26% to 29%) for parecoxib-treated patients versus opioids.
Based on model estimates of total cost and values for each of the
model outcomes, incremental cost-effectiveness analysis suggests
that parecoxib therapy is more effective and less costly than
opioid therapy. CONCLUSIONS: Results from this model
suggest that the opioid-sparing properties of parecoxib translate
into better clinical outcomes, reduced health care resource uti-
lization, and lower costs versus an opioid-only pain management
strategy.
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OBJECTIVES: In moderate postoperative pain a weak opioid in
combination with a non-opioid analgesic is recommended. Cor-
responding ﬁxed combinations with paracetamol include the
weak opioid tramadol or codeine. The objective of this study was
to determine the cost-effectiveness of the tramadol/paracetamol
combination (Zaldiar®) in comparison to a codeine/paracetamol
combination (with a ratio of 1 :10; codeine :paracetamol) for
postoperative pain after arthroscopic procedures or abdominal
